Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FID-022 in Advanced Solid Tumors
NCT06694480Phase 1Recruiting
- Sponsor
- Fulgent Pharma
- Start
- Jul 2025
- Primary completion
- Dec 2027
- Modality
- Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of FID-022 in solid tumor (advanced stage) (2 arms), sponsored by Fulgent Pharma. Primary endpoints: Maximum Tolerated Dose at 2.5 years, Treatment-related Adverse Events at 2.5 years and 1 more. Started Jul 2025; status: recruiting.
02
Drugs
FID-022
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT06694480.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06694480.